Hima Sapa1, Orlando M Gutiérrez2, Michael G Shlipak3, Ronit Katz4, Joachim H Ix5, Mark J Sarnak6, Mary Cushman7, Eugene P Rhee8, Paul L Kimmel9, Ramachandran S Vasan10, Sarah J Schrauben11, Harold I Feldman11, Jesse C Seegmiller12, Henri Brunengraber13, Thomas H Hostetter14, Jeffrey R Schelling15. 1. Division of Nephrology, Department of Internal Medicine, University Hospitals Cleveland, School of Medicine, Case Western Reserve University, Cleveland, Ohio. 2. Departments of Medicine and Epidemiology, University of Alabama, Birmingham, Alabama. 3. Kidney Health Research Collaborative and Department of Medicine, San Francisco Veterans Administration Medical Center and University of California-San Francisco, San Francisco, California. 4. Kidney Research Institute, University of Washington, Seattle, Washington. 5. Division of Nephrology and Hypertension, Department of Medicine, University of California-San Diego, San Diego, California. 6. Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts. 7. Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont. 8. Division of Nephrology, Department of Medicine, Massachusetts General Hospital and Harvard University, Boston, Massachusetts. 9. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. 10. Departments of Medicine and Epidemiology, School of Medicine and School of Public Health, Boston University, Boston, Massachusetts. 11. Renal Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 12. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota. 13. Department of Nutrition, School of Medicine, Case Western Reserve University, Cleveland, Ohio. 14. Division of Nephrology, Department of Internal Medicine, University Hospitals Cleveland, School of Medicine, Case Western Reserve University, Cleveland, Ohio; Division of Nephrology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina. 15. Division of Nephrology, Department of Internal Medicine, MetroHealth Campus, School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, Ohio. Electronic address: jeffrey.schelling@case.edu.
Abstract
RATIONALE & OBJECTIVE: Cardiovascular disease (CVD) is a major cause of mortality among people with diabetic kidney disease (DKD). The pathophysiology is inadequately explained by traditional CVD risk factors. The uremic solutes trimethylamine-N-oxide (TMAO) and asymmetric and symmetric dimethylarginine (ADMA, SDMA) have been linked to CVD in kidney failure with replacement therapy (KFRT), but data are limited in populations with diabetes and less severe kidney disease. STUDY DESIGN: Observational cohort. SETTINGS & PARTICIPANTS: Random subcohort of 555 REGARDS (Reasons for Geographic and Racial Differences in Stroke) study participants with diabetes and estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 at study entry. EXPOSURE: ADMA, SDMA, and TMAO assayed by liquid chromatography-mass spectrometry in plasma and urine. OUTCOME: Cardiovascular mortality (primary outcome); all-cause mortality and incident KFRT (secondary outcomes). ANALYTICAL APPROACH: Plasma concentrations and ratios of urine to plasma concentrations of ADMA, SDMA, and TMAO were tested for association with outcomes. Adjusted Cox regression models were fitted and hazard ratios of outcomes calculated per standard deviation and per doubling, and as interquartile comparisons. RESULTS: The mean baseline eGFR was 44 mL/min/1.73 m2. Cardiovascular death, overall mortality, and KFRT occurred in 120, 285, and 89 participants, respectively, during a mean 6.2 years of follow-up. Higher plasma ADMA and SDMA (HRs of 1.20 and 1.28 per 1-SD greater concentration), and lower ratios of urine to plasma concentrations of ADMA, SDMA, and TMAO (HRs per halving of 1.53, 1.69, and 1.38) were associated with cardiovascular mortality. Higher plasma concentrations of ADMA, SDMA, and TMAO (HRs of 1.31, 1.42, and 1.13 per 1-SD greater concentration) and lower urine to plasma ratios of ADMA, SDMA, and TMAO (HRs per halving of 1.34, 1.37, and 1.26) were associated with all-cause mortality. Higher plasma ADMA and SDMA were associated with incident KFRT by categorical comparisons (HRs of 2.75 and 2.96, comparing quartile 4 to quartile 1), but not in continuous analyses. LIMITATIONS: Single cohort, restricted to patients with diabetes and eGFR < 60 mL/min/1.73 m2, potential residual confounding by GFR, no dietary information. CONCLUSIONS: Higher plasma concentrations and lower ratios of urine to plasma concentrations of uremic solutes were independently associated with cardiovascular and all-cause mortality in DKD. Associations of ratios of urine to plasma concentrations with mortality suggest a connection between renal uremic solute clearance and CVD pathogenesis.
RATIONALE & OBJECTIVE: Cardiovascular disease (CVD) is a major cause of mortality among people with diabetic kidney disease (DKD). The pathophysiology is inadequately explained by traditional CVD risk factors. The uremic solutes trimethylamine-N-oxide (TMAO) and asymmetric and symmetric dimethylarginine (ADMA, SDMA) have been linked to CVD in kidney failure with replacement therapy (KFRT), but data are limited in populations with diabetes and less severe kidney disease. STUDY DESIGN: Observational cohort. SETTINGS & PARTICIPANTS: Random subcohort of 555 REGARDS (Reasons for Geographic and Racial Differences in Stroke) study participants with diabetes and estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 at study entry. EXPOSURE: ADMA, SDMA, and TMAO assayed by liquid chromatography-mass spectrometry in plasma and urine. OUTCOME: Cardiovascular mortality (primary outcome); all-cause mortality and incident KFRT (secondary outcomes). ANALYTICAL APPROACH: Plasma concentrations and ratios of urine to plasma concentrations of ADMA, SDMA, and TMAO were tested for association with outcomes. Adjusted Cox regression models were fitted and hazard ratios of outcomes calculated per standard deviation and per doubling, and as interquartile comparisons. RESULTS: The mean baseline eGFR was 44 mL/min/1.73 m2. Cardiovascular death, overall mortality, and KFRT occurred in 120, 285, and 89 participants, respectively, during a mean 6.2 years of follow-up. Higher plasma ADMA and SDMA (HRs of 1.20 and 1.28 per 1-SD greater concentration), and lower ratios of urine to plasma concentrations of ADMA, SDMA, and TMAO (HRs per halving of 1.53, 1.69, and 1.38) were associated with cardiovascular mortality. Higher plasma concentrations of ADMA, SDMA, and TMAO (HRs of 1.31, 1.42, and 1.13 per 1-SD greater concentration) and lower urine to plasma ratios of ADMA, SDMA, and TMAO (HRs per halving of 1.34, 1.37, and 1.26) were associated with all-cause mortality. Higher plasma ADMA and SDMA were associated with incident KFRT by categorical comparisons (HRs of 2.75 and 2.96, comparing quartile 4 to quartile 1), but not in continuous analyses. LIMITATIONS: Single cohort, restricted to patients with diabetes and eGFR < 60 mL/min/1.73 m2, potential residual confounding by GFR, no dietary information. CONCLUSIONS: Higher plasma concentrations and lower ratios of urine to plasma concentrations of uremic solutes were independently associated with cardiovascular and all-cause mortality in DKD. Associations of ratios of urine to plasma concentrations with mortality suggest a connection between renal uremic solute clearance and CVD pathogenesis.
Authors: Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard Journal: Neuroepidemiology Date: 2005-06-29 Impact factor: 3.282
Authors: Lesley A Inker; Nwamaka D Eneanya; Josef Coresh; Hocine Tighiouart; Dan Wang; Yingying Sang; Deidra C Crews; Alessandro Doria; Michelle M Estrella; Marc Froissart; Morgan E Grams; Tom Greene; Anders Grubb; Vilmundur Gudnason; Orlando M Gutiérrez; Roberto Kalil; Amy B Karger; Michael Mauer; Gerjan Navis; Robert G Nelson; Emilio D Poggio; Roger Rodby; Peter Rossing; Andrew D Rule; Elizabeth Selvin; Jesse C Seegmiller; Michael G Shlipak; Vicente E Torres; Wei Yang; Shoshana H Ballew; Sara J Couture; Neil R Powe; Andrew S Levey Journal: N Engl J Med Date: 2021-09-23 Impact factor: 176.079
Authors: Rainer H Böger; Lisa M Sullivan; Edzard Schwedhelm; Thomas J Wang; Renke Maas; Emelia J Benjamin; Friedrich Schulze; Vanessa Xanthakis; Ralf A Benndorf; Ramachandran S Vasan Journal: Circulation Date: 2009-03-16 Impact factor: 29.690
Authors: Thimoteus Speer; Lucia Rohrer; Przemyslaw Blyszczuk; Rukshana Shroff; Kira Kuschnerus; Nicolle Kränkel; Gabriela Kania; Stephen Zewinger; Alexander Akhmedov; Yi Shi; Tina Martin; Damir Perisa; Stephan Winnik; Maja F Müller; Urban Sester; Gabriel Wernicke; Andreas Jung; Ursula Gutteck; Urs Eriksson; Jürgen Geisel; John Deanfield; Arnold von Eckardstein; Thomas F Lüscher; Danilo Fliser; Ferdinand H Bahlmann; Ulf Landmesser Journal: Immunity Date: 2013-03-07 Impact factor: 31.745
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Emilie H Zobel; Bernt Johan von Scholten; Henrik Reinhard; Frederik Persson; Tom Teerlink; Tine W Hansen; Hans-Henrik Parving; Peter K Jacobsen; Peter Rossing Journal: Cardiovasc Diabetol Date: 2017-07-11 Impact factor: 9.951
Authors: Robert A Koeth; Zeneng Wang; Bruce S Levison; Jennifer A Buffa; Elin Org; Brendan T Sheehy; Earl B Britt; Xiaoming Fu; Yuping Wu; Lin Li; Jonathan D Smith; Joseph A DiDonato; Jun Chen; Hongzhe Li; Gary D Wu; James D Lewis; Manya Warrier; J Mark Brown; Ronald M Krauss; W H Wilson Tang; Frederic D Bushman; Aldons J Lusis; Stanley L Hazen Journal: Nat Med Date: 2013-04-07 Impact factor: 53.440